In the PACIFIC phase III randomized clinical trial, consolidative programmed death ligand‐1 (PD‐L1) inhibition using durvalumab following cCRT was associated with significant improvements in both the progression‐free survival (PFS) and OS of these NSCLC patients relative to cCRT alone.9, 10, 11. Here, CD274 is linked to non-small cell lung carcinoma.